tbuckley/cabot-search huggingface dataset:
First year of cardiac transplantation.
Journal: BMJ (1969)

PointersCar Accidents: Study of 50 fractures or frac- ture dislocations of the hip suggests that central fracture dislocations are the result of direct force on the great trochanter (p.71).Bronchopneumonia in Children: After an out- break of bronchopneumonia in young children in New Zealand a high proportion were left with lung damage.Adenovirus type 21 was implicated (p.73).E.C.G.Changes in Hypertension: T-wave inversion and S-T segment depression considered not to indicate impaired cardiac function (p. 79).Urban Tuberculosis: "Total efficiency" of supervised intermittent therapy claimed to be greater than that of unsupervised daily regimens (p.82).Bundle-branch Block: Assessment of clinical implications of finding this sign in acute myocardial infarction (p. 85).Unusual Tumour: Giant-cell carcinoma of lung producing much plasminogen activator.Haemo- stasis achieved with aminocaproic acid (p.88).Bradycardiac Angina: Due to inability to increase heart rate on exercise (p.92).Encephalitogenic Viruses: Successful tissue- culture (p. 94).Case Reports: Guillain-Barr6 syndrome in typhoid (p.95).Porphyria in alcoholic (p.96).Lead-poisoning from home-made cider (p.98).
Genome-Wide Promoter Methylation Of Hairy Cell Leukemia (HCL)
Authors: Andrea Rinaldi, Ivo Kwee, Afua A. Mensah, Davide Rossi, Meena Kanduri, Richard Rosenquist, Emanuele Zucca, Gianluca Gaidano, Francesco Bertoni, Francesco Forconi
Journal: Blood (2013)
Peptide libraries for the comprehensive coverage of the tumor mutanome for immune monitoring and immuno therapy
Authors: Paul von Hoegen, Tobias Knaute, Holger Wenschuh, Ulf Reimer
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Many cancers are associated with functional mutations which now can be readily identified using new DNA sequencing methods. Sequence information is now used for the generation of personalized cancer vaccines with promising clinical benefit [1]. Intelligent ways to select the
Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).
Authors: Dung T. Le, Todd S. Crocenzi, Jennifer N. Uram, Eric R. Lutz, Daniel A. Laheru, Elizabeth A. Sugar, Robert H. Vonderheide, George A. Fisher, Andrew H. Ko, Aimee L. Murphy, Katherine McDougall, Sandy Ferber, Dirk G. Brockstedt, Elizabeth M. Jaffee
Journal: Journal of Clinical Oncology (2015)

TPS4148 Background: A heterologous prime-boost vaccination strategy using GVAX pancreas vaccine and CRS-207 is showing promise in patients with pancreatic adenocarcinoma (PDA) (Le, JCO 2015). Furthermore, blockade of the immune checkpoint programmed death-1 (PD-1) is active in some cancers. Combinatorial strategies aimed at priming tumor antigen-specific T cells while simultaneously blocking negative checkpoints may be necessary to improve outcomes in PDA. GVAX is composed of allogeneic pancreatic cancer cells modified to express GM-CSF and induces a broad response against multiple tumor antigens. GVAX is given with low-dose cyclophosphamide (CY) to inhibit regulatory T cells. CRS-207 is live-attenuated Listeria monocytogenes engineered to express the tumor-associated antigen mesothelin. CRS-207 boosts responses against mesothelin and is unique in its capacity to stimulate both innate and adaptive immunity by activating T cells and NK cells. Nivolumab is an antibody against PD-1. Methods: This is a phase 2 study comparing CY/GVAX and CRS-207 with or without nivolumab in subjects with PDA who failed only one chemotherapy regimen for metastatic disease. Subjects are randomized in a 1:1 ratio to receive either 2 doses of CY/nivolumab/GVAX and 4 doses of nivolumab/CRS-207 (Arm A) or 2 doses of CY/GVAX and 4 doses of CRS-207 (Arm B). The primary objective is to compare OS between Arms A and B. Secondary/exploratory objectives include: assessment of safety and clinical responses (tumor assessments and CA19-9 levels) and correlation of Lm- and mesothelin-specific T cell and other immunological responses with OS, progression-free survival and best overall response. Clinical trial information: NCT02243371. Clinical trial information: NCT02243371.
Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion
Authors: Daeun Ryu, Seok Jin Kim, Yourae Hong, Areum Jo, Nayoung Kim, Hee-Jin Kim, Hae-Ock Lee, Kihyun Kim, Woong-Yang Park
Journal: Clinical Cancer Research (2019)

Abstract Purpose: In multiple myeloma, extramedullary progression is associated with treatment resistance and a high mortality rate. To understand the molecular mechanisms controlling the devastating progression of myeloma, we applied single-cell RNA-sequencing (RNA-seq) to myeloma in the bone marrow and myelomatous pleural effusions or ascites. Experimental Design: Bone marrow or extramedullary myeloma samples were collected from 15 patients and subjected to single-cell RNA-seq. The single-cell transcriptome data of malignant plasma cells and the surrounding immune microenvironment were analyzed. Results: Comparisons of single-cell transcriptomes revealed the systematic activation of proliferation, antigen presentation, proteasomes, glycolysis, and oxidative phosphorylation pathways in extramedullary myeloma cells. The myeloma cells expressed multiple combinations of growth factors and receptors, suggesting autonomous and pleiotropic growth potential at the single-cell level. Comparisons of the tumor microenvironment revealed the presence of cytotoxic T lymphocytes and natural killer (NK) cells in both the bone marrow and extramedullary ascites, demonstrating a gene-expression phenotype indicative of functional compromise. In parallel, isolated myeloma cells persistently expressed class I MHC molecules and upregulated inhibitory molecules for cytotoxic T and NK cells. Conclusions: These data suggest that myeloma cells are equipped with specialized immune evasion mechanisms in cytotoxic microenvironments. Taken together, single-cell transcriptome analysis revealed transcriptional programs associated with aggressive myeloma progression that support autonomous cell proliferation and immune evasion.
Rehabilitation Oncology
Authors: Henry H. Stonnington
Journal: JAMA (1981)

The author and publishers of<i>Rehabilitation Oncology</i>are to be congratulated on producing one of the first books on this subject. The book should be of interest to all oncologists and physiatrists. It is brief and concise and touches on all pertinent areas. The introduction deals with the general principle of cancer rehabilitation. The second chapter deals with how the cancer rehabilitation program is set up. Naturally enough, as the author was instrumental in the setting up and running of the Sloan-Kettering Memorial Hospital Cancer Rehabilitation program, he uses that program as a model. The third chapter, which forms the bulk of the book, deals with the various cancer sites and the rehabilitation needs of the cancer patient relative to particular sites. Finally there are two brief chapters, one on general support, which includes nutrition, psychological and social problems and community resources, and employment problems, and the other on how
Fibromodulin as a Novel Tumor-Associated Antigen (TAA) in Chronic Lymphocytic Leukemia (CLL) Which Allows Expansion of Specific CD8+ Autologous T Lymphocytes.
Authors: Christine Mayr, Dagmar Bund, Martin Schlee, Andreas Moosmann, Michael Hallek, Clemens Wendtner
Journal: Blood (2004)
Increased rate of tolbutamide metabolism in alcoholic patients
Authors: R. M. Kater
Journal: JAMA (1969)

In a controlled human study the biological half-life of tolbutamide was found to be reduced more than twofold in alcoholic patients. We suggest that this effect is the result of stimulation by alcohol of a hepatic microsomal enzyme system in the human liver responsible for the metabolism of tolbutamide. The metabolism of other therapeutic agents could be similarly affected by alcohol, and this might lead to irregularities in response to drug treatment.
SINGLE-SESSION BRIDGE-TO-SURGERY CHOLEDOCHO-DUODENOSTOMY AND DUODENAL STENTING IN PATIENT WITH MALIGNANT BILIARY AND DUODENAL OBSTRUCTION
Authors: M Manno, S Deiana, L Ottaviani, S Vavassori, T Gabbani, P Soriani
Journal: Endoscopy (2020)

This´s the case of a 73-year-old-man affected by obstructive jaundice,cholangitis and vomit due to resectable pancreatic-head cancer. Secondary duodenal infiltration not allowed to reach the Vater’s papilla and choledocho-duodenostomy(EUS-CD)was performed. 8mm x 8mm LAMSwas deployed, obtaining biliary drainage. In the same session, uncovered 60mm x 10 mm SEMS was deployed across the 30 mm duodenal stenosis. CT-scan confirmed stents correct position. Progressive jaundice resolution was observed; the patient restarted oral feeding; he was referred to oncologic surgical treatment. In patients with malignant distal biliary and duodenal obstruction, single-session EUS-CD and duodenal stenting is challenging for the risk of LAMS dislocation,but feasible and effective. It doesn’t compromise further surgical treatment and it can be considered as a bridge-to-surgery approach.
Cardiovascular effects of tricyclic and tetracyclic antidepressants
Authors: D. Burckhardt
Journal: JAMA (1978)

Cardiovascular effects of therapeutic doses of tricyclic or tetracyclic antidepressants (TCA) were examined in 66 patients. After three weeks of therapy, heart rate and PR interval were increased (<i>P</i>&lt;.02,<i>P</i>&lt;.05), while prolongation of the QT<sub>c</sub>time and the QRS interval did not reach significant levels. We observed significant flattening of T waves (<i>P</i>&lt;.05), which was not associated with changes in the serum potassium level. These changes were reversible after treatment was discontinued. When therapy was maintained for 13 months, only the heart rate continued to be increased, whereas all other ECG values had returned to normal. The TCA therapy led to a significant prolongation of the preejection period (<i>P</i>&lt;.01) and slight shortening of the left ventricular ejection time, indicating a decrease in myocardial contractility. There was no difference of effects on the values studied between tricyclic and tetracyclic antidepressants. (<i>JAMA</i>239:213-216, 1978)
Help stamp out mandatory continuing education!
Authors: G. N. Libby
Journal: JAMA (1975)

Mandatory continuing education programs for health professionals, as they are now administered, are predictable failures. Such programs may destroy the will to learn. Objective studies indicate that current continuing education programs do not influence the methods of practice of the health professional. Current programs are primarily pedagogical, reflecting the philosophies and techniques of child-youth education. Present methods of program evaluation are sorely inadequate. Adults may be coerced into attendance, but learning and subsequent application of knowledge may not be forced. Future continuing education programs should be problem-centered. The adult practitioner must become actively involved in the planning and execution of these programs. (<i>JAMA</i>233:797-799, 1975)
THE LYMPHATICS IN TUBERCULOSIS
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Psychotropic drugs in use today. The role of diazepam in medical practice
Authors: B. Blackwell
Journal: JAMA (1973)

Until the discovery of chlorpromazine in 1952, there were no specific drug treatments in psychiatry, only sedatives and stimulants. The efficacy of chlorpromazine hydrochloride in schizophrenia began a hunt for other specific remedies leading to the discovery of imipramine hydrochloride for depression in 1957, followed by several newer sedatives supposedly specific for neurotic anxiety and called "minor tranquilizers." These arrived between 1957 and 1965 and included hydroxyzine hydrochloride (Atarax, Vistaril), meprobamate (Equanil, Miltown), and the benzodiazepines (Librium, Valium, and Serax). In addition, combinations of so-called antidepressants and tranquilizers have become available and new or older drugs now are claimed to have dual actions in treating both anxiety and depression. Since these drugs became available, there have been many studies of which drugs should be used in particular conditions. By way of contrast, this review examines what drugs are actually being used and what types of illness they are prescribed to
Disease Transmission in the Dental Office: Guidelines for Disinfection
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Strawberry Gums
Authors: Paul S. Cohen
Journal: JAMA (1981)

WEGENER'S granulomatosis is a systemic illness that encompasses necrotizing vasculitis and granulomatous infiltration of the upper and lower respiratory tract and significant renal involvement. Medical journals<sup>1</sup>have reported gingival involvement in Wegener's granulomatosis, but this phenomenon has been described more extensively in the dental literature.<sup>2-5</sup>We report the case of a patient with Wegener's granulomatosis in whom distinctive diagnostic gingival changes were present from the beginning of his illness but were not recognized as physical findings indicative of Wegener's granulomatosis. Because these gingival lesions are not well described in the medical literature, we report the following case. <h3>Report of a Case</h3> A 57-year-old man was referred for evaluation of recent-onset hemoptysis and two days of fevers with shaking chills on Jan 21, 1980. Several months of progressive shortness of breath, a nonhealing lesion on his left arm, and polyarthralgias were also noted. Four months before admission, a chest roentgenogram
A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC).
Authors: Avivit Peer, Avivit Neumann, Daniel Keizman, Stephen Jay Frank, Raanan Berger, Larisa Leitzin, Ester Pinto, Victoria Neiman, Eli Rosenbaum
Journal: Journal of Clinical Oncology (2015)

e15531 Background: For patients with advanced TCC who have progressed on a platinum-based regimen, no widely accepted standard second line therapy currently exists. A 2-stage phase II study was conducted to assess the activity and toxicity profile of the microtubule inhibitor cabazitaxel (Jevtana; FDA-approved in hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen) in patients with metastatic TCC after failure of prior platinum-based chemotherapy. ClinicalTrials.gov NCT01600339. Methods: Patients with one prior platinum based systemic therapy for metastatic TCC received cabazitaxel at a dose of 25 mg\m2every 21 days with prophylactic GCSF support, until disease progression or unacceptable toxicity. The primary endpoint was objective tumor response rate (ORR). Secondary endpoints included safety, time to progression (TTP), and overall survival (OS). Results: Twenty-three patients were enrolled to the study, 19 of whom received treatment. Male\female ratio was 15\4 and the median age was 67 (range, 56-81) years. Partial response (PR) was observed in 1 patient (5.3%), 10 patients (52.6%) achieved stable disease (SD), including 8 (42.1%) that had prolonged SD ( ≥ 16 weeks).Furthermore, the disease control rate (PR or prolonged SD) was 47.4%. At a median follow up of 10.1 months, all patients progressed and 16/19 (84%) died. The median TTP and OS were 4.2 (95% CI, 2.0-6.0) months and 9.9 (95% CI 5.6-13.2) months, respectively. The median number of treatment cycles was 5 (range 1-10). One patient experienced Grade 5 toxicity. Neutropenic fever occurred in 10.6% of patients. Most common toxicities were anemia and diarrhea. Conclusions: Cabazitaxel had modest efficacy in the treatment of advanced TCC, and there was no evidence of a significant response. Toxicity profile was considerable. The role of Cabazitaxel in urothelial carcinoma may need further evaluation in rational combination strategies, but not as a single agent. Clinical trial information: NCT01600339.
Study of Possible Relationship of Progesterone to Colic
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hypnosis in medicine.
Journal: BMJ (1968)

Leading Articles B~67institutions is an old craft, at which the British are said to excel.Sometimes, however, it is better to be less spectacular and adapt the old tradition to the new circumstances, and this the College is doing with notable success.But among to- day's circumstances is an increasing intrusion of politics and bureaucracy on medicine.Professional institutions have a special duty to see that professional initiatives remain where they belong.Fortunately the College has a long experience to draw upon.
Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use
Authors: M. J. Reinhart
Journal: JAMA (1966)

Evidence suggestive of hepatotoxicity concomitant with the use of the antipsychotic tranquilizer thioridazine hydrochloride was seen in three cases. The first case with a history of increased serum glutamic oxaloacetic transaminase (SGOT) levels while taking chlorpromazine (Thorazine) responded to thioridazine with elevated values of alkaline phosphatase and serum glutamic pyruvic transaminase (SGPT). Clinical jaundice was noted. The second case with a history of parkinsonism and photosensitivity reaction on chlorpromazine presented with an increase in SGPT levels which progressively rose under continued administration of thioridazine. Concurrent pruritus, fatigue, and dark-colored urine accompanied the elevated transaminase levels. In the third case, SGPT and alkaline phosphatase values rose with thioridazine usage. Despite these findings, treatment with the medication (thioridazine) was maintained with a resultant return to normal values of the SGPT and alkaline phosphatase.
Letter from the Chairman of the Board to members of the House of Delegates
Authors: W. W. Hall
Journal: JAMA (1966)

On June 29, 1966, Resolution 104 was adopted by the House of Delegates of the American Medical Association at the annual convention in Chicago. Subsequently, and after due deliberation, the Board of Trustees voted unanimously (1) that this resolution should not be implemented by the AMA, and (2) that constituent and component medical societies be advised, likewise, to refrain from implementing Resolution 104. This letter is intended to inform you of the sequence of events and the reasons for the unusual action taken by the Board of Trustees. The action of the Board of Trustees was taken pursuant to article VIII of the AMA Constitution, section 163a16 of the Illinois General Not-For-Profit Corporation Act, and the following statement of policy adopted by the House of Delegates in June, 1955, at Atlantic City, NJ: It is the understanding of the Board of Trustees that prior to any action on the implementation
A Text-Book of Pathology.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal